Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
11 hedge funds and large institutions have $2.41M invested in Evoke Pharma in 2014 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
8% more capital invested
Capital invested by funds: $2.23M → $2.41M (+$184K)
0% more funds holding
Funds holding: 11 → 11 (0)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
California Public Employees Retirement System
Sacramento,
California
|
+$210K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$44.6K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$32.2K |
| 4 |
Morgan Stanley
New York
|
+$5.78K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$2.48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$154K |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
-$131K |
| 3 |
Barclays
London,
United Kingdom
|
-$2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.65K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OM
1
Opaleye Management
Boston,
Massachusetts
| $1.42M | -$154K | -187 | -10% |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $287K | – | – | – |
|
|
CWG
3
C WorldWide Group
Copenhagen,
Denmark
| $266K | – | – | – |
|
|
4
California Public Employees Retirement System
Sacramento,
California
| $243K | +$210K | +255 | New |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| $93K | +$32.2K | +39 | +55% |
|
|
6
Bank of America
Charlotte,
North Carolina
| $91K | +$44.6K | +54 | +102% |
|
|
7
Morgan Stanley
New York
| $6K | +$5.78K | +7 | New |
|
|
BIM
8
BlackRock Investment Management
Wilmington,
Delaware
| $3K | – | – | – |
|
|
9
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $2K | +$2.48K | +3 | New |
|
10
UBS Group
Zurich,
Switzerland
| $2K | +$2.48K | +3 | New |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $1K | -$1.65K | -2 | -67% |
|
|
LP
12
LMR Partners
London,
United Kingdom
| – | -$131K | -166 | Closed |
|
|
13
Barclays
London,
United Kingdom
| – | -$2K | -3 | Closed |
|
EVOK Hedge Fund Activity: Q4 2014 in Review
11 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q4 2014, worth a combined $2.41M — up 8.2% from $2.23M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new EVOK positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was California Public Employees Retirement System, opening a new position worth an estimated $210K. The largest seller was Opaleye Management, cutting an estimated $154K.
- 11 institutional investors held Evoke Pharma (EVOK) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $2.41M of Evoke Pharma stock for Q4 2014, up 8.2% quarter-over-quarter.
- 4 funds opened new Evoke Pharma positions in Q4 2014 and 2 closed out, a net change of +2 holders.
- The largest Evoke Pharma buyer in Q4 2014 was California Public Employees Retirement System, an estimated $210K added.
- The largest Evoke Pharma seller in Q4 2014 was Opaleye Management, an estimated $154K sold.
Based on aggregated 13F filings for Q4 2014.